FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, in particular to a selected monoclonal antibody, which specifically binds to human poliovirus receptor (PVR), or to its fragment, as well as to a composition containing it. Polynucleotide encoding a sequence of variable area of light or heavy chain of the specified antibody, as well as a plasmid and a cell containing it are also disclosed.
EFFECT: invention allows for effective diagnostics or treatment of cancer in a subject.
31 cl, 16 dwg, 4 tbl, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HUMAN NECTIN-2 SPECIFIC ANTIBODIES | 2020 |
|
RU2820275C2 |
| ANTI-C5 ANTIBODIES AND THEIR USE | 2018 |
|
RU2774716C2 |
| ACTIVATOR OF REGULATORY T CELLS AND USE THEREOF | 2017 |
|
RU2736650C2 |
| HUMANIZED ANTI-C5 ANTIBODIES AND THEIR APPLICATION | 2019 |
|
RU2792237C2 |
| MONOCLONAL ANTIBODIES AGAINST HUMAN TIM-3 | 2019 |
|
RU2777336C1 |
| METHODS FOR TREATING CANCER, INCLUDING TIGIT-BINDING AGENTS | 2017 |
|
RU2765410C2 |
| AIMED AT UPARAP ANTIBODY-DRUG CONJUGATES | 2017 |
|
RU2740311C2 |
| NOVEL MONOCLONAL ANTIBODIES TO LAM AND PIM6/LAM FOR DIAGNOSING AND TREATING INFECTIONS CAUSED BY MYCOBACTERIUM TUBERCULOSIS | 2017 |
|
RU2732502C2 |
| EGFL6-SPECIFIC MONOCLONAL ANTIBODIES AND THEIR APPLICATION METHODS | 2017 |
|
RU2779902C2 |
| TREATING CANCER USING A CHIMERIC ANTIGENIC CLL-1 RECEPTOR | 2015 |
|
RU2741120C2 |
